Rett Syndrome Stocks

Biopharmaceutical firms in this space target a rare, X-linked neurodevelopmental disorder characterized by the loss of motor and communication skills, focusing on therapeutic modalities that address underlying MECP2 gene mutations.

As of Oct 23, 2026, Rett Syndrome has 4 US-listed companies worth $5.5B combined. The median member moved +2.4% over the past week; TSHA led at +9.4% and NGNE trailed at +1.3%.